Skip to content

A Study to Quantify Tumour Perfusion for Spine Metastasis Treated With Stereotactic Body Radiotherapy (SBRT)

Reduction in Tumour Perfusion for Spine Metastasis Treated With Stereotactic Body Radiotherapy (SBRT)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03072979
Enrollment
18
Registered
2017-03-08
Start date
2017-01-21
Completion date
2018-12-31
Last updated
2017-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spine Metastasis

Brief summary

Pre-clinical evidence suggests that radiotherapy reduces tumour-associated vasculature. The investigators will conduct a single-arm prospective study to quantify the reduction in tumour vasculature post-radiotherapy

Interventions

RADIATIONStereotactic body radiotherapy

Stereotactic body radiotherapy

Sponsors

National University of Singapore
CollaboratorOTHER
National University Hospital, Singapore
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥21 years of age * Proven metastatic disease, excluding haematological and germ cell neoplasms * Life expectancy \>3 months, Eastern Cooperative Oncology group (ECOG) 0-2

Exclusion criteria

* The patient must not have an allergy to gadolinium contrast that will limit the ability to image the tumour by MRI safely even with the use of premedication * eGFR \< 30 mL/min or if patient is suffering from acute renal insufficiency * Prior radiotherapy to the specified region * Recent surgery to affected spinal levels, or patients requiring immediate surgical intervention * Spinal instability score (SINS) \>12 * Symptomatic cord compression (Bilksy grade 2 or 3), or worsening neurological deficits * Body weight of more than 120kg * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Reduction in vasculature3 monthReduction in vasculature measured by changes on Dynamic Contrast enhanced MRI

Countries

Singapore

Contacts

Primary ContactBALAMURUGAN VELLAYAPPAN, MBBS, FRANZCR
bala_vellayappan@nuhs.edu.sg67795555

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026